Dr. Brodie Best Known for Role in Developing Aromatase InhibitorsBALTIMORE, March 28, 2013 /PRNewswire-USNewswire/ -- Angela H. Brodie, Ph.D., a University of Maryland scientist whose research paved the way for a new class of drugs widely used to treat breast cancer patients around the world, has been selected by the American Association for Cancer Research (AACR) as a fellow of the newly created AACR Academy. Dr. Brodie, professor of pharmacology at the University of Maryland School of Medicine and scientist at the University of Maryland Marlene and Stewart Greenebaum Cancer Center, is one of 106 fellows who will be inducted into the AACR Academy on April 5, 2013, at a ceremony in Washington, D.C. AACR said it created the academy "to recognize and honor distinguished scientists whose major scientific contributions have propelled significant innovation and progress against cancer." The inaugural class of scientists was selected through a rigorous peer review process. According to AACR, the number of fellows in the class symbolizes the age of the Philadelphia-based professional organization dedicated to advancing cancer research, which was founded in 1907. "Our Board of Directors made the decision to establish the AACR Academy as a mechanism for recognizing scientists whose contributions to the cancer field have had an extraordinary impact," says Margaret Foti, Ph.D., M.D. (h.c.), AACR's chief executive officer. "Membership in the Fellows of the AACR Academy will be the most prestigious honor bestowed by the American Association for Cancer Research." Dr. Brodie's research laid the groundwork for a class of drugs called aromatase inhibitors, which help to prevent recurrence of breast cancer in postmenopausal women by reducing estrogen produced by the body, thereby cutting off fuel to the cancer cells. The drugs inhibit the production of aromatase, an enzyme that plays a key role in the biosynthesis of estrogen.